Module 5 Quiz Questions Flashcards
What molecule does Tamoxifen bind to?
Estrogen Receptor
What settings may Tamoxifen be used in to treat breast cancer?
- Risk reduction
- Adjuvant Therapy
- Metastatic breast cancer
Match end points for EORTC trial (Tamoxifen vs Exemestane)
- median PFS exemestane
- median PFS tamoxifen
- median OS exemestane
- median OS tamoxifen
- median PFS exemestane - 9.9 months
- median PFS tamoxifen - 5.8 months
- median OS exemestane - 37.2 months
- median OS tamoxifen - 43.3 months
What is the mechanism of action of Letrozole?
inhibits conversion of androgens to estrogen
In what settings can letrozole be used to treat breast cancer?
- Neo adjuvant
- Adjuvant and extended adjuvant
- Metastic
- NOT risk reduction
What was the mean TTP in patients receiving letrozole in the study comparing letrozole to megestrol acetate as second line therapy in post menopause with advanced Metastatic cancer?
23.6%
What is the mechanism of action of anastrozole?
Inhibits the conversion of androgens to estrogens
In what settings can anastrozole be used to treast BC?
- neo
- adj
- metastic
- all the above
What percentage of patients in the North American trial receiving anastrozole achieved OR?
21%
What enzyme does exemestane inhibit?
Aromatase
In what settings can exemestane be used to treat BC?
Neo
Adj
Metastatic
*** NOT risk reduction
Which end points showed a significant advantage for exemestane in a phase 3 trial?
Survival
Overall Success
TTP
*** NOT OR
What is the mechanism of action for fulvestrant?
competitively inhibits binding of estrogen to the estrogen receptor
In what settings can fulvestrant be used to treat BC?
metastatic breast cancer
What is the dose and method of admin for fulvestrant?
500 IM
In the CONFIRM study, PFS was significantly longer for Fulvestrant 500mg corresponding to a ………. reduction in the risk of progression
20%
In the CONFIRM trial which of the following was a serious AE reported more than 2 patients
dyspnea
What is the mechanism of action of everolimus?
inhibitor of mTor
In what settings may everolimus be used to treat BC?
metastatic breast cancer
In the BOLERO-2 study the median PFS based on local assessment …….. months for combination vs. …… months for the extremestane alone group?
- 9 months
2. 8 months
In the BOLERO-2 study which of the following was one of the most common grade 3 or 4 AE reported in the combination therapy group?
stomatitus
